VGXI Introduces New Manufacturing Facility

VGXI, Inc., a contract development and manufacturing organization (CDMO) that works with nucleic acid biopharmaceuticals including gene therapies, DNA vaccines, and RNA medicines, has unveiled its new headquarters and manufacturing facility located at Deison Technology Park in Conroe, TX.

To ensure a seamless transition and provide additional overflow capacity, the CDMO's existing facility in The Woodlands will remain fully operational.

The 120,000 square-foot Conroe building contains four manufacturing trains with state-of-the-art production equipment, fermentation capacity in excess of 3000L, and expanded good manufacturing practice (GMP) fill-finish capabilities. Dedicated areas are also available for mRNA manufacturing and small-scale, rapid turnaround services for personalized therapies.

“The new VGXI headquarters is ready to support our clients as they achieve successful late phase and commercial launch of their products,” notes CEO Young Park. “Combined with our highly skilled and dedicated team, we are confident VGXI will continue to meet the growing industry demand for these next-generation medicines.”